Effects of Bifidobacterium animalis subsp. lactis BB-12® on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial

Table 6 Fecal SCFAs of participants at baseline and after 4 weeks of the YS, PRE, POST, or CAPSULE treatment period^a,b

Variables	BL (n = 30)	YS (n = 25)	PRE (n = 25)	POST (n = 26)	CAP (n = 26)	P-value*
Total SCFAs, μg/g	2533 ± 208	2818 ± 219	2823 ± 216	2517 ± 220	2654 ± 219	0.66
Acetate, μg/g	701 ± 68	914 ± 71**	900 ± 70**	773 ± 71	780 ± 71	0.05
Propionate, μg/g	527 ± 47	633 ± 50	602 ± 49	529 ± 50	560 ± 50	0.32
Butyrate, μg/g	798 ± 86	889 ± 91	921 ± 90	755 ± 91	865 ± 91	0.55

^aValues are means ± SEMs; BL, baseline; YS, yogurt smoothie with no BB-12^®; PRE, yogurt smoothie with BB-12^® added pre-fermentation; POST, yogurt smoothie with BB-12^® post-fermentation; SCFAs, short chain fatty acids
^bStatistical analyses were calculated using sex, treatment as between subject factor and randomization ID as the within-subject factor and age, BMI, fiber intake as covariates
*P values are for the main effect of treatment
** Values are significantly difference from baseline (P < 0.01)

ISSN: 1475-2891